Development of an anti-Chlamydia vaccine for the koala

为考拉开发抗衣原体疫苗

• 批准号: LP0990147
• 负责人: Prof Peter Timms
• 金额: $ 20.34万
• 依托单位: Queensland University of Technology
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-07-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0990147
• 关键词: Development; anti; Chlamydia; vaccine; koala

The koala is one of Australia's main icons and a major drawcard for tourists. However, it suffers from debilitating disease due to the bacterium Chlamydia, which can lead to severe conjunctivitis, eventual blindness in both sexes, and the females develop untreatable cysts and can become infertile. This project will develop a Chlamydia vaccine to be administered to healthy and diseased koalas in zoos, sanctuaries, koala care centres, relocation programs and eventually perhaps even wild populations. The vaccine findings may also be transferable to other animals and may also even assist the development of a human Chlamydia vaccine.

考拉是澳大利亚的主要标志之一，也是吸引游客的一大亮点。然而，由于衣原体细菌，它会患上使人衰弱的疾病，这种疾病会导致严重的结膜炎，最终导致男女失明，雌性会出现无法治疗的囊肿，并可能变得不育。该项目将开发一种衣原体疫苗，用于动物园、保护区、考拉护理中心、重新安置项目中健康和患病的考拉，最终甚至可能用于野生种群。疫苗的发现也可以转移到其他动物身上，甚至可以帮助开发人类衣原体疫苗。